Market Overview

UPDATE: Goldman Sachs Reiterates Neutral Rating, Lowers PT for Alkermes

Related ALKS
Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest EPS Growth Forecast For Next 5 Years
Non-Opioid Therapeutics And Significant Pain Treatments Make For A Buy Rating
Ad Comm approaches for Fabre-Kramer's MDD med (Seeking Alpha)

In a company update published earlier today, the Goldman Sachs Group, Inc. reiterated its Neutral rating for Alkermes, plc (NASDAQ: ALKS) and slightly lowered its price target from $18.00 to $17.00.

Goldman Sachs went on to say “ALKS saw $46 mn in revenues from JNJ's Consta and Sustenna, slightly ahead of our $44 mn. Vivitrol sales of $11 mn (+4% q/q) were in line with our estimate, but slightly below consensus of $12 mn. Vivitrol FY2013 guidance of $45-$55 mn was below our estimate of $69 mn, and we are reducing our estimates, which drives a decrease in our price target. We are also adjusting our top- and bottom-line estimates to reflect quarterly trends.”

Alkermes, plc closed yesterday at $16.71

Latest Ratings for ALKS

Nov 2015Leerink SwannMaintainsOutperform
Oct 2015BarclaysMaintainsOverweight
Oct 2015BarclaysMaintainsOverweight

View More Analyst Ratings for ALKS
View the Latest Analyst Ratings

Posted-In: Goldman Sachs Group Inc.Analyst Color Price Target Reiteration Analyst Ratings


Related Articles (ALKS)

View Comments and Join the Discussion!

Get Benzinga's Newsletters